2026 Q1 Portfolio Activity
In 2026 Q1, Vestal Point Capital, LP maintained a portfolio of 113 distinct positions. The most significant new addition was Neurocrine Biosciences Inc, now representing 4.60% of the total fund value. They heavily accumulated shares in Revolution Medicines Inc, increasing the position by 705.1%. Conversely, Vestal Point Capital, LP completely exited their position in Invesco QQQ Trust Series 1.
Position History
hover any row below to update
Loading…
Total Positions
113
Quarter
2026 Q1
Top Holding
RVMD (6.5%)
Top 10 Concentration
40.4%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 113
Vestal Point Capital, LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RVMD
Revolution Medi...
|
Healthcare | 6.46% | 0.80% |
#1
34
Prev: #35
|
7.6 |
—
|
2,080,000 | 705.1% |
P
S
|
2,375,000 | $230,968,750 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BMRN
BioMarin Pharma...
|
Healthcare | 5.65% | 6.06% |
#2
3
Prev: #5
|
5.8 |
—
|
575,000 | 19.2% |
P
S
|
3,575,000 | $201,951,750 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ABVX
Abivax SA
|
Healthcare | 4.67% | 8.71% |
#3
2
Prev: #1
|
2.9 |
—
|
-400,000 | -21.1% |
P
S
|
1,500,000 | $167,025,000 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NBIX
Neurocrine Bios...
|
Healthcare | 4.60% | — |
#4
Prev: #—
|
5.8 |
—
|
1,250,000 | — |
NEW
|
1,250,000 | $164,675,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ARWR
Arrowhead Pharm...
|
Healthcare | 3.99% | 2.03% |
#5
11
Prev: #16
|
5.1 |
—
|
1,375,000 | 152.8% |
P
S
|
2,275,000 | $142,642,500 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ELVN
Enliven Therape...
|
Healthcare | 3.56% | 2.01% |
#6
11
Prev: #17
|
1.9 |
—
|
-580,000 | -15.1% |
P
S
|
3,250,000 | $127,400,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RGEN
Repligen Corp
|
Healthcare | 3.05% | 0.46% |
#7
37
Prev: #44
|
4.2 |
—
|
842,000 | 1014.5% |
P
S
|
925,000 | $108,983,500 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCAX
Bicara Therapeu...
|
Healthcare | 3.02% | 2.05% |
#8
7
Prev: #15
|
4.2 |
—
|
1,850,000 | 51.7% |
P
S
|
5,425,000 | $107,903,250 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NRIX
Nurix Therapeut...
|
Healthcare | 2.82% | 3.02% |
#9
2
Prev: #7
|
3.6 |
—
|
1,810,000 | 38.6% |
P
S
|
6,500,000 | $100,750,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
APGE
Apogee Therapeu...
|
Healthcare | 2.59% | 1.41% |
#10
13
Prev: #23
|
4.0 |
—
|
550,000 | 100.0% |
P
S
|
1,100,000 | $92,587,000 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ASND
Ascendis Pharma...
|
Healthcare | 2.40% | 1.27% |
#11
15
Prev: #26
|
4.0 |
—
|
200,000 | 114.3% |
P
S
|
375,000 | $85,773,750 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMCR
Immunocore Hold...
|
Healthcare | 2.33% | 0.69% |
#12
25
Prev: #37
|
3.9 |
—
|
2,181,868 | 373.0% |
P
S
|
2,766,868 | $83,421,070 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TSHA
Taysha Gene The...
|
Healthcare | 2.25% | 2.57% |
#13
2
Prev: #11
|
3.4 |
—
|
4,250,000 | 30.9% |
P
S
|
18,000,000 | $80,460,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DYN
Dyne Therapeuti...
|
Healthcare | 2.03% | 0.08% |
#14
55
Prev: #69
|
3.8 |
—
|
3,880,000 | 3233.3% |
P
S
|
4,000,000 | $72,520,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SNY
Sanofi SA
|
Healthcare | 1.89% | — |
#15
Prev: #—
|
4.3 |
—
|
1,400,000 | — |
NEW
|
1,400,000 | $67,452,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BCRX
BioCryst Pharma...
|
Healthcare | 1.87% | 0.60% |
#16
25
Prev: #41
|
3.7 |
—
|
4,775,000 | 212.2% |
P
S
|
7,025,000 | $66,878,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SRRK
Scholar Rock Ho...
|
Healthcare | 1.82% | 1.05% |
#17
13
Prev: #30
|
3.7 |
—
|
624,422 | 89.2% |
P
S
|
1,324,422 | $65,108,586 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IMTX
Immatics NV
|
Healthcare | 1.70% | 2.19% |
#18
5
Prev: #13
|
1.2 |
—
|
50,000 | 0.8% |
P
S
|
6,175,000 | $60,762,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BMY
Bristol-Myers S...
|
Healthcare | 1.70% | 0.46% |
#19
27
Prev: #46
|
3.7 |
—
|
750,000 | 300.0% |
P
S
|
1,000,000 | $60,650,000 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ALC
Alcon AG
|
Healthcare | 1.69% | 2.96% |
#20
12
Prev: #8
|
0.7 |
—
|
-305,000 | -27.6% |
P
S
|
800,000 | $60,280,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 1.66% | 0.41% |
#21
26
Prev: #47
|
3.7 |
—
|
2,828,465 | 365.0% |
P
S
|
3,603,465 | $59,276,999 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VERA
Vera Therapeuti...
|
Healthcare | 1.54% | 0.95% |
#22
10
Prev: #32
|
3.6 |
—
|
818,159 | 148.8% |
P
S
|
1,368,159 | $55,041,037 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
TERN
Terns Pharmaceu...
|
Healthcare | 1.47% | 6.18% |
#23
19
Prev: #4
|
0.6 |
—
|
-3,500,000 | -77.8% |
P
S
|
1,000,000 | $52,720,000 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
GMED
Globus Medical ...
|
Healthcare | 1.47% | 3.78% |
#24
18
Prev: #6
|
0.6 |
—
|
-664,480 | -52.1% |
P
S
|
610,520 | $52,602,403 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BSX
Boston Scientif...
|
Healthcare | 1.40% | — |
#25
Prev: #—
|
4.1 |
—
|
800,000 | — |
NEW
|
800,000 | $50,200,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NUVL
Nuvalent Inc
|
Healthcare | 1.38% | 0.16% |
#26
37
Prev: #63
|
3.6 |
—
|
435,715 | 947.2% |
P
S
|
481,715 | $49,351,702 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
COGT
Cogent Bioscien...
|
Healthcare | 1.32% | — |
#27
Prev: #—
|
4.0 |
—
|
1,230,888 | — |
NEW
|
1,230,888 | $47,376,879 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
ANRO
Alto Neuroscien...
|
Healthcare | 1.30% | 1.50% |
#28
6
Prev: #22
|
1.0 |
—
|
-420,925 | -16.9% |
P
S
|
2,064,075 | $46,400,406 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
RAPP
Rapport Therape...
|
Healthcare | 1.26% | 1.14% |
#29
2
Prev: #27
|
3.0 |
—
|
326,229 | 29.4% |
P
S
|
1,436,229 | $44,939,605 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
IRON
Disc Medicine I...
|
Healthcare | 1.25% | 1.98% |
#30
12
Prev: #18
|
1.0 |
—
|
-35,000 | -4.8% |
P
S
|
700,000 | $44,758,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
UTHR
United Therapeu...
|
Healthcare | 1.24% | — |
#31
Prev: #—
|
4.0 |
—
|
75,000 | — |
NEW
|
75,000 | $44,473,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CLDX
Celldex Therape...
|
Healthcare | 1.09% | 1.08% |
#32
3
Prev: #29
|
2.4 |
—
|
59,165 | 5.1% |
P
S
|
1,224,165 | $38,830,514 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
KALV
KalVista Pharma...
|
Healthcare | 1.04% | 1.04% |
#33
2
Prev: #31
|
0.9 |
—
|
-40,000 | -2.1% |
P
S
|
1,850,000 | $37,240,500 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
XENE
Xenon Pharmaceu...
|
Healthcare | 1.04% | 0.91% |
#34
1
Prev: #33
|
2.4 |
—
|
39,900 | 6.7% |
P
S
|
639,900 | $37,210,185 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLDB
Solid Bioscienc...
|
Healthcare | 1.01% | 1.12% |
#35
7
Prev: #28
|
0.9 |
—
|
-815,000 | -14.0% |
P
S
|
5,000,000 | $36,000,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DRUG
Bright Minds Bi...
|
Healthcare | 1.00% | — |
#36
Prev: #—
|
3.9 |
—
|
492,319 | — |
NEW
|
492,319 | $35,924,517 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
PTGX
Protagonist The...
|
Healthcare | 0.96% | — |
#37
Prev: #—
|
3.9 |
—
|
326,159 | — |
NEW
|
326,159 | $34,377,159 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
DNLI
Denali Therapeu...
|
Healthcare | 0.95% | 0.26% |
#38
15
Prev: #53
|
3.4 |
—
|
1,308,326 | 281.4% |
P
S
|
1,773,326 | $34,047,859 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
REGN
Regeneron Pharm...
|
Healthcare | 0.86% | — |
#39
Prev: #—
|
3.8 |
—
|
40,000 | — |
NEW
|
40,000 | $30,905,600 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
WAT
Waters Corp
|
Healthcare | 0.83% | — |
#40
Prev: #—
|
3.8 |
—
|
100,000 | — |
NEW
|
100,000 | $29,780,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
VKTX
Viking Therapeu...
|
Healthcare | 0.83% | — |
#41
Prev: #—
|
3.8 |
—
|
914,147 | — |
NEW
|
914,147 | $29,746,343 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
INSP
Inspire Medical...
|
Healthcare | 0.78% | — |
#42
Prev: #—
|
3.8 |
—
|
539,269 | — |
NEW
|
539,269 | $27,815,495 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
N/A
Crescent Biopha...
|
|
Unknown | 0.77% | 0.60% |
#43
3
Prev: #40
|
1.3 |
—
|
no change | no change |
P
S
|
1,500,000 | $27,555,000 | — | 13F Filing | 2026-03-31 | 2026-05-15 | ||
|
TRVI
Trevi Therapeut...
|
Healthcare | 0.72% | — |
#44
Prev: #—
|
3.8 |
—
|
2,166,504 | — |
NEW
|
2,166,504 | $25,846,393 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
LXEO
Lexeo Therapeut...
|
Healthcare | 0.72% | 1.51% |
#45
24
Prev: #21
|
1.3 |
—
|
no change | no change |
P
S
|
4,475,000 | $25,686,500 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SLNO
Soleno Therapeu...
|
Healthcare | 0.68% | — |
#46
Prev: #—
|
3.8 |
—
|
730,000 | — |
NEW
|
730,000 | $24,440,400 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
BBNX
Beta Bionics In...
|
Healthcare | 0.62% | 0.62% |
#47
8
Prev: #39
|
3.2 |
—
|
1,611,518 | 268.6% |
P
S
|
2,211,518 | $22,159,410 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
NKTR
Nektar Therapeu...
|
Healthcare | 0.57% | — |
#48
Prev: #—
|
3.7 |
—
|
285,000 | — |
NEW
|
285,000 | $20,505,750 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
CYTK
Cytokinetics In...
|
Healthcare | 0.55% | — |
#49
Prev: #—
|
3.7 |
—
|
300,000 | — |
NEW
|
300,000 | $19,773,000 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
AZNCF
AstraZeneca PLC
|
Unknown | 0.55% | — |
#50
Prev: #—
|
3.7 |
—
|
100,000 | — |
NEW
|
100,000 | $19,722,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-50 of 113 holdings